Vutrisiran reduces days lost to death and/or hospitalization versus placebo in patients with transthyretin amyloidosis with cardiomyopathy in the HELIOS-B trial
29 August 2025 (07:00 - 18:00)
Organised by: 

About the speaker

Cleveland Clinic Main Campus, Cleveland (United States of America)
6 More presentations in this session

Doctor A. Arenas Loriente (Barcelona, ES)

Doctor I. Santos (Ponta Delgada, PT)

Doctor J. Chen (Zurich, CH)
Access the full session
The Event
ESC Congress 2025
29 August - 1 September 2025
You may be interested in
Congress Session
Congress Session


